Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical mechanistic evidence
PubMed 41683613 · doi:10.3390/ijms27031186
What was done
This narrative review synthesized preclinical and clinical evidence examining the cellular and molecular mechanisms by which semaglutide affects adipose tissue biology in type 2 diabetes mellitus (T2DM). The authors evaluated depot-specific changes, lipid handling, mitochondrial function, beige adipocyte induction, cytokine secretion, immunometabolic shifts, and extracellular matrix remodeling.
What was found
The abstract reports qualitative mechanistic pathways rather than quantitative primary data or pooled effect estimates. The review describes that semaglutide induces a functional shift in adipose tissue toward an oxidative, insulin-sensitive phenotype via improved mitochondrial biogenesis, reduced fibrosis and extracellular matrix stiffness, modified adipokine profiles, and beige programming across subcutaneous and visceral depots.
Why it matters
It highlights that semaglutide's therapeutic benefits in T2DM likely extend beyond appetite suppression and glucose control to direct biological remodeling of dysfunctional adipose tissue.
Limits
The abstract notes that most mechanistic evidence derives from in vitro systems and animal models. Quantitative human data, study counts, and precise clinical effect sizes are not reported in the abstract, and direct human molecular profiling and longitudinal imaging studies remain limited.
Cited by
- supports GLP-1 receptor agonist medications affect the immune system through actions on adipocytes.